Rheumatoid Arthritis.

Slides:

Advertisements

Similar presentations

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Advertisements

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

A NEW LOOK AT RA Interactive Hot Topics Series

Upfront Combination Therapy vs Step-Up Approach for PAH:

Rheumatoid arthritis The Lancet

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

My Treatment Approach to Rheumatoid Arthritis

Psoriatic Arthritis.

Introduction/Background

Clinical Developments in Inflammatory Arthritis 2017

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Updates on Emerging GLP-1 Receptor Agonists

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Current and Emerging Treatments for IBD

Diagnosing Rheumatoid Arthritis Early

Access to NOAC Therapy:

Part 1: Disease Activity Measures

Biosimilars in RA: A Blessing or a Curse?

SGLT2 Inhibitors in Phase 3 Trials

Expert Insights on Psoriatic Arthritis From Washington, DC

My Treatment Approach to Rheumatoid Arthritis

Novel Small Molecule Therapies in Rheumatoid Arthritis

Comparing Treatment Alternatives in Ankylosing Spondylitis

Surveying the Safety of NOACs in the Real World

Minding the Gap Rheumatoid Arthritis Advances From London 2016

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Clinical Updates in RA: New Developments and Insights From Washington

Is it Time for a Paradigm Change in HIV Management?

Access to NOAC Therapy:

Is RA Treatment Addressing the Real Needs of Patients?

Next-Gen Psoriasis Therapies:

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Emerging Atopic Dermatitis Treatments:

What’s new in my specialty- Rheumatoid Arthritis

Evolving Treatment Landscape for PsA

Biotherapeutics.

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

Advances in Rheumatoid Arthritis Management

What's New in Therapeutic Options for Moderate to Severe RA?

Advancing Patient Care in RA

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Critical Decision Points in Insomnia

Update on the Management of Atopic Dermatitis

Updates in RA, PsA, and Biosimilars

Improving Effective Basal Insulin Use in Clinical Practice

Patient disposition through 48 weeks in RA-BEYOND

Giant Cell Arteritis.

Peanut Allergy Immunotherapy

AMD Therapy: Where Are We Now and Where Are We Going?

Real-World Evidence.

Nat. Rev. Rheumatol. doi: /nrrheum

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Patient disposition after 2 years of treatment.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Treatment Advances for RA

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Biosimilars in Immune-Related Diseases

What's New in NOACs in AF?.

Psoriatic Arthritis.

You Don't Know JAK in IBD.

Presentation transcript:

Rheumatoid Arthritis

Introduction

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab

JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus

Currently Available JAK Inhibitors for RA

Early vs Delayed Start of Baricitinib in Patients Naive to MTX Treatment

MTX Withdrawal in Patients Who Achieve LDA With Tofacitinib MR 11 mg QD + MTX

Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to MTX

Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to DMARDs

FINCH1: Efficacy and Safety of Filgotinib in MTX-IR Patients

FINCH3: Efficacy and Safety of Filgotinib in MTX-Naive Patients

FINCH2: Subgroup Analyses

Switching Between Upadacitinib and ADA Following Initial Non-Response

Upadacitinib SELECT Trials: 48-Week Results

Fenebrutinib Compared to PBO and ADA in MTX-IR or TNF-IR Patients

Safety and Efficacy of LY3337641 in Patients With RA: Phase 2 Study

Subcutaneous Administration of Infliximab Biosimilar (CT-P13)

Concluding Remarks

Abbreviations

Abbreviations (cont)